Serum-free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders
- 25 Downloads
Post-transplant lymphoproliferative disease (PTLD) is a serious complication of solid organ transplantation. As early diagnosis remains challenging, we investigated the utility of serum-free light chain (FLC) and heavy chain/light chain pairs (HLC) as diagnostic biomarkers. Pre-treatment serum FLC and HLC levels were measured in 20 patients at their first diagnosis of B cell PTLD and in 14/20 patients during follow-up. Results were compared to serum FLC/HLC levels of 90 matched PTLD-free transplanted controls. Renal dysfunction was common in both cohorts, and combined FLC levels were often elevated above the conventional upper limit of normal (45.7 mg/L). Combined FLC levels were higher in patients with PTLD than in transplant controls (p = 0.013), and levels above the conventional ULN were associated with PTLD (OR 3.2, p = 0.05). Following adjustment to cystatin C as a marker of renal function an even stronger association was found for a (dimensionless) threshold value of 37.8 (OR 8.9, p < 0.001). In addition, monoclonal proliferation (abnormal FLC ratio, using an established renal range cutoff) was more common in PTLD than in controls (3/20 vs. 2/90, p = 0.04). Following therapy, at the time of protocolised restaging, patients experiencing subsequent sustained complete remission displayed lower FLC levels than those not experiencing such remission (p = 0.053). No relationship with HLC results was seen. Elevated polyclonal FLC levels (especially when adjusted for renal function) and monoclonal proliferation are a potential biomarker for PTLD diagnosis and disease surveillance. However, prospective validation is necessary before FLC measurement should be incorporated in follow-up of transplant recipients and PTLD management.
KeywordsPTLD Serum-free light chain Serum-free heavy chain Biomarker
Chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone
Combined free light chain
Diffuse large B cell lymphoma
Eastern Cooperative Oncology Group
Free light chain
Adjusted free light chain
Serum heavy/light chain
Mucosal-associated lymphoid tumour
Post-transplant lymphoproliferative disorder
Receiver operating characteristic
Upper limit of normal
We thank the Binding Site Ltd. for the provision of the assays for this study and for technical support, in particular, Dr. Anne Burmeister.
RB and RUT are the principal investigators, coordinated the research and take primary responsibility for the paper. HZ, HR and RUT recruited the patients and collected clinical data. FB, RB and PC recruited the controls. AS did the laboratory work. AS, RB, PC and RUT analysed and interpreted the data. IA served as reference pathologists. AS, RB, PC, HZ and RUT wrote the paper. All authors had full access to the final version of the manuscript and agreed to publication.
Compliance with ethical standards
Ethical approval for this study was provided by the local committees of both institutions. The study was conducted according to the guidelines of the Declaration of Helsinki.
The Binding Site provided FLC, HLC and cystatin C assays free of charge. The Binding Site played no role in the analysis of the clinical data, its interpretation or the manuscript preparation. The content of the manuscript remains the responsibility of the listed authors.
Conflicts of interest
The authors declare that they have no conflict of interest.
Informed consent was obtained from all individual participants included in the study.
- 1.Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, Weisenburger DD, Martínez-Maza O, Hussain SK, Yang J, Chang ET, Engels EA (2013) Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer 109(1):280–288. https://doi.org/10.1038/bjc.2013.294 CrossRefGoogle Scholar
- 5.Fernando RC, Rizzatti EG, Braga WMT, Santos MG, de Oliveira MB, Pestana JOM, Baiocchi OCG, Colleoni GWB (2013) Serum free light chains and post-transplant lymphoproliferative disorder in patients with renal transplant. Leuk Lymphoma 54(10):2177–2180. https://doi.org/10.3109/10428194.2013.764423 CrossRefGoogle Scholar
- 7.Jardin F, Delfau-Larue MH, Molina TJ, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Jais JP, Figeac M, Leroy K, Mareschal S, Salles GA, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Haioun C, Tilly H (2013) Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. Leuk Lymphoma 54(9):1898–1907. https://doi.org/10.3109/10428194.2013.767456 CrossRefGoogle Scholar
- 9.Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD). The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13(2):196–206. https://doi.org/10.1016/S1470-2045(11)70300-X CrossRefGoogle Scholar
- 10.Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, van den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S (2017) Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, Multicenter Phase II Trial. J Clin Oncol 35(5):536–543. https://doi.org/10.1200/JCO.2016.69.3564 CrossRefGoogle Scholar
- 12.Katzmann JA, Clark RJ, Abraham RS et al (2002) Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48(9):1437–1444Google Scholar
- 13.Trappe R, Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, Lehmkuhl H, Gartner B, Anagnostopoulos I, Riess H (2011) Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica 96(7):1067–1071. https://doi.org/10.3324/haematol.2010.039214 CrossRefGoogle Scholar
- 15.Bradwell AR, Carr-Smith HD, Mead GP et al (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47(4):673–680Google Scholar